Clinical trials: Parkinson
Parkinson Disease
Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of four single oral doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa/benserazide 100/25…
- Trial name
- NCT03091543
- Testing
- Madopar® HBS 125, BIA 6-512 25 mg dose, BIA 6-512 50 mg dose
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
This open label extension study allows assessment of the long term safety profile of REQUIP PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.
- Trial name
- NCT01536574
- Testing
- Requip PR
- Where
- 18 sites in China
- Volunteers
- 295 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Randomised, double-blind, double dummy, parallel group design. Following the screening period patients will be randomised at the baseline visit, in a 1:1:1 manner, to one of three treatment arms; 4 mg E2007, 200 mg entacapone…
- Trial name
- NCT00360308
- Testing
- E2007
- Where
- France
- Volunteers
- 723 people
- Sponsor
- Eisai Limited
Advanced Parkinson Disease
Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- ENVOL (NCT06639620)
- Where
- 33 sites in France
- Volunteers
- 250 people
- Sponsor
- AbbVie
Parkinson Disease
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
This is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to be conducted in conformance with Good…
- Trial name
- NCT00845000
- Testing
- SCH 420814 10 mg, SCH 420814 100 mg, Levodopa
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)
An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
- Trial name
- NCT00862537
- Testing
- Resonator Device
- Volunteers
- 18 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Parkinson's Disease (PD)
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement.
- Trial name
- NCT05916157
- Where
- 17 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AbbVie
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
- Trial name
- NCT05258071
- Testing
- Pirepemat
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 104 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson's Disease
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of…
- Trial name
- NCT05603312
- Testing
- AAV-GAD Low Dose, AAV-GAD High Dose
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- MeiraGTx, LLC
Parkinson's Disease, HIV Infections
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS).
- Trial name
- NCT00990379
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Salena Killion
Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in Parkinson's Disease patients who have "wearing off" motor fluctuations and "on" period dyskenisias.
- Trial name
- NCT01172379
- Testing
- E2007
- Where
- 33 sites in Czechia, France and 4 more
- Volunteers
- 2 people
- Sponsor
- Eisai Limited
Parkinson's Disease
A Trial of MitoQ for the Treatment of People With Parkinson's Disease
In Parkinson's Disease, the mitochondrial membranes in cells that produce dopamine become damaged by oxidants, leading to the death of these cells and progressive tremor, slowness of movement and the loss of neurons in the…
- Trial name
- NCT00329056
- Testing
- MitoQ
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 128 people
- Sponsor
- Antipodean Pharmaceuticals, Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Gait Disorders, Neurologic
Digital GaitCare - Therapy Monitoring in the Home Environment of Patients With Parkinson
Gait disturbances and movement restrictions occur frequently in Parkinson's disease. Patient-centered monitoring with objective aids in the patient's daily life, supports and promotes therapy decisions made by physicians and…
- Trial name
- NCT04931303
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Parkinson Disease, Idiopathic Parkinson Disease
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's…
- Trial name
- NCT01215227
- Testing
- Preladenant, Rasagiline
- Volunteers
- 839 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Quality-of-Life Index (Q-Index)
The main objective of this observational study is to use commonly-used connected objects (smartphones and smartwatches) to remotely assess and monitor the health-related quality of life (HrQoL) of people with Parkinson's disease…
- Trial name
- NCT06209502
- Where
- 4 sites in Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Koios Care
Parkinson's Disease
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
- Trial name
- NCT04165837
- Testing
- FB-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.